血清大脑衍生的神经营养因子水平作为阿尔茨海默病进展的预测因素
Meng-Ju Tsai1,2, Yung-Shuan Lin1,2,3,4,5,6,7, Chun-Yu Chen1,2,4
1Division of General Neurology, Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Journal of the Chinese Medical Association : JCMA
|September 15, 2023
概括
高血清脑源性神经营养因子 (BDNF) 水平表明阿尔茨海默病 (AD) 患者的认知衰退速度较慢. 这表明BDNF可能是预防AD进展的保护因素,有助于将病理与临床症状联系起来.
科学领域:
- 神经科学是一个神经科学.
- 老年学是一门学科.
- 生物化学 生物化学
背景情况:
- 大脑衍生神经营养因子 (BDNF) 与阿尔茨海默病 (AD) 病理生理学有关.
- 较低的外围BDNF水平与AD风险增加相关.
- 这项研究研究了血清BDNF作为AD进展的预测因子.
研究的目的:
- 为了确定血清BDNF水平是否可以预测阿尔茨海默病患者认知能力下降的速度.
- 探索血清BDNF水平与认知测试表现之间的关系.
主要方法:
- 长度观察性研究,98名认知正常参与者和442名AD患者.
- 使用迷你精神状态检查 (MMSE),记忆,口语流性和命名测试来评估认知功能.
- 测量了血清BDNF水平和APOE等位基因状态;根据MMSE得分变化,分析了阿尔茨海默病患者的进展到快速和缓慢下降.
主要成果:
- 较高的血清BDNF水平与阿兹海默症患者认知能力下降的速度较慢显著相关.
- 血清BDNF水平与多项神经心理测试的表现有正相关性.
- 逻辑回归表明血清BDNF是缓慢认知衰退的预测因素,独立于年龄,性别,APOE4状态,教育和基线MMSE.
结论:
- BDNF作为一种保护因素,可以防止阿尔茨海默病的进展.
- 血清BDNF水平可能成为预测AD进展和认知衰退的有价值生物标志物.
- BDNF可能弥合了AD病理和可观察到的临床症状之间的差距.
更多相关视频
07:22Assessment of Blood-brain Barrier Permeability by Intravenous Infusion of FITC-labeled Albumin in a Mouse Model of Neurodegenerative Disease
Published on: November 8, 2017
10.0K
07:28Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
Published on: May 19, 2022
3.8K
相关概念视频
Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
